The effectiveness of cytocardioprotection of patients with the moderately expressed post infarct dysfunction of left heart ventricle: the results of the randomization research of trimetazidine and athenolole
https://doi.org/10.20538/1682-0363-2002-1-40-44
Abstract
With the purpose of research of clinical efficiency of trimetazidine and atenolol and their influence on morfofunctional parameteres of left ventricle 36 men who have transferred a myocardial infarction are inspected. Patients were randomly divided into 2 groups. Clinical status and function state of left ventricle (by echocardiography) was assessed before and after 4-week therapy with trimetazidine or atenolol. Atenolol and trimetazidine have shown in our study identical clinical efficiency. However while atenolol is statistically significant reduced systolic arterial pressure and heart rate, thickness of posterior wall of left ventricle and corrects diastolic function, trimetazidine had no such activity. Treatment with trimetazidine promoted improvement of local contractility of left ventricle.
About the Authors
V. V. Kalyuzhin
Сибирский государственный медицинский университет
Russian Federation
Russian Federation
M. A. Solovtsov
Сибирский государственный медицинский университет
Russian Federation
Russian Federation
D. U. Kamaev
Сибирский государственный медицинский университет
Russian Federation
Russian Federation
References
1. Кокурина Е.В., Бочкарева Е.В., Метелица В.И., Бутина Е.К. Антиишемическая эффективность триметазидина в комбинации с пропранололом у больных со стабильной стенокардией напряжения//Кардиоогия. 2000. № 5. С. 10-14.
2. Шабалин А.В., Никитин Ю.П. Защита кардиомиоцита. Современное состояние и перспективы//Кардиология. 1999. Т. 39, № 3. С. 4-10.
3. Kantor P.F. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitohondrial Long-Chain 3-Ketoacyl-Coenzym A Thiolase/P.F. Kantor, A. Lucien, R. Kozak, G.D. Lopaschuk//Circ. Res. 2000. V. 86. P. 580-588.
4. Бузиашвили Ю.И., Маколкин В.И., Осадчий К.К., Асымбекова Э.У., Ахмедярова Н.К., Старовойтова С.П. Влияние триметазидина на обратимую дисфункцию миокарда при ишемической болезни сердца//Кардиология. 1999. №6. С. 33-38.
5. Терещенко С.Н. Цитопротектор триметазидин в комплексной терапии тяжелой постинфарктной хронической сердечной недостаточности/С.Н. Терещенко, О.С. Акимова, И.В. Демидова//Кардиология. 1999. № 9. С. 48-52.
6. Lu C., Dabrowski P., Fragasso G., Chierchia S.L. Effect of trimetazidine on ischemic coronary artery disease//Am. J. Cardiol. 1998. V. 82. P. 898-901
7. Беленков Ю.Н. Дисфункция левого желудочка у больных ИБС: современные методы диагностики, медикаментозной и не медикаментозной коррекции//Рус. мед. журн. 2001. № 17. С. 3-10.
8. Detry J.M., Sellier P., Pennaforte S., Cokkinos D., Mathes P. Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina//Br. J. Clin. Pharmacol. 1994. V. 37. P. 279-288.
Review
For citations:
Kalyuzhin V.V., Solovtsov M.A., Kamaev D.U. The effectiveness of cytocardioprotection of patients with the moderately expressed post infarct dysfunction of left heart ventricle: the results of the randomization research of trimetazidine and athenolole. Bulletin of Siberian Medicine. 2002;1(1):40-44. (In Russ.) https://doi.org/10.20538/1682-0363-2002-1-40-44
Views:
459
Email this article 